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A key focus and strength of health psychology is the development and evaluation of 1 
interventions, programmes and strategies (herein called ‘interventions’) across a spectrum of 2 
health conditions to improve health and well-being across the life-span. Findings of reviews 3 
and meta-analyses of trials of health psychology interventions influence intervention 4 
implementation. This in turn impacts significantly on patient and public health, and 5 
healthcare services (Heneghan, Goldacre, & Mahtani, 2017).  6 
Choice of outcomes is a crucial consideration in the planning and conduct of trials of health 7 
interventions (Heneghan et al., 2017), in synthesising evidence about intervention effects 8 
(Clarke, 2007), and in producing clinical practice guidelines (Health, 2014). Outcomes, in 9 
this context, are what we examine to determine effects of interventions on aspects of health 10 
relating to benefits and harms. Outcome measurement instruments (OMIs) are how we 11 
measure these outcomes. Choice of outcomes can influence sample sizes, data sources, and 12 
length of follow-up in trials (Velentgas, 2013). Tugwell et al. (2007) argue that a trial is only 13 
as good as its outcomes, as intervention effects can only be inferred from those outcomes 14 
measured and reported. Interpretations of intervention effects can influence research and 15 
applications of health psychology findings in practice (Gargon et al., 2018). Outcome choice 16 
therefore has the potential to impact on clinical care, including changes to existing practice or 17 
introduction of new treatments. The aim of this paper is to introduce and discuss approaches 18 
to determining what outcomes to measure in health psychology research, as well as how to 19 
measure these outcomes. To do this, we outline existing issues with outcome selection and 20 
reporting, introduce core outcome sets (COSs), outline best practice guidelines in how to 21 
develop and measure COSs, and discuss benefits and potential challenges of COSs in health 22 
psychology.  23 
 24 
Current issues in outcome selection and reporting 25 
Considerable heterogeneity in outcomes evaluated and reported across trials significantly 26 
limits interpretability and synthesis of intervention effects (Jones & Kaplan, 2003; 27 
Schmucker et al., 2014). Examination of outcome heterogeneity across health psychology 28 
trials is scarce, as are concerted efforts to address potential heterogeneity within the 29 
discipline. This is particularly true in relation to trials of intervention for health behaviours 30 
such as diet, physical activity, and medication adherence. However heterogeneity has been 31 
examined and reported for a number of outcomes relevant to health psychology to date. For 32 
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instance, a recent review of 405 trials of brief alcohol interventions identified 2,641 unique 33 
outcomes (Shorter et al., 2019). A review of 126 infant feeding studies in the context of 34 
childhood obesity prevention also reported significant heterogeneity in outcomes, with 15% 35 
of outcomes reported only once (Matvienko-Sikar, Griffin, et al., 2018); the two most 36 
frequently reported outcomes were reported in only just over half of the reviewed studies 37 
(Matvienko-Sikar, Toomey, et al., 2017). Similarly, reviews of interventions to increase 38 
physical activity include a range of physical activity outcomes, including step counts, energy 39 
expenditure, and type, frequency, intensity and duration of physical activity (Carr et al., 40 
2019; Lock et al., 2020; Malik, Blake and Suggs, 2013; McEwan et al., 2016). Further, one 41 
recent review (Lock et al., 2020) noted variations in observed effectiveness of physical 42 
activity interventions based on type of outcome examined (e.g. step-based outcomes, minutes 43 
of exercise, metabolic equivalents or energy expenditure). Heterogeneous approaches to 44 
evaluating health outcomes highlight a lack of consensus about what should be measured, 45 
with potential implications for reported effectiveness of health psychology interventions.  46 
 47 
Similar issues have been observed with heterogeneous use and reporting of OMIs.  In a 48 
review of 10,000 trials of 1940 interventions for schizophrenia, 2194 different measurement 49 
instruments were used; 1142 of these measurement scales were used only once (Miyar et al., 50 
2013). Similarly, a recent review of OMIs for depression and anxiety identified 80 different 51 
OMIs (Obbarius et al., 2017). Though research has not specifically focused on potential 52 
heterogeneity in how health psychology relevant outcomes are measured, variability in 53 
measurement approaches can be seen in existing reviews. For instance a recent review of 54 
medication adherence noted that adherence can be measured by self-report, pill count, 55 
electronic medication monitors, and pharmacy refill records (Morrissey et al., 2017); this 56 
heterogeneity has been noted over 20 years of empirical research on medication adherence 57 
(Holmes et al., 2014). Heterogeneity of outcomes and OMIs significantly limits synthesis of 58 
effects to determine the most efficacious interventions (Clarke, 2007).  59 
 60 
Core Outcome Sets 61 
An approach to potentially address issues of outcome heterogeneity described above, is the 62 
development and use of standardised approaches to outcome measurement and reporting. 63 
Core outcome sets (COS) represent one such approach. COSs are the standardised minimum 64 
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set or group of agreed-upon outcomes that should be measured and reported in any trial of a 65 
specific health area (Williamson et al., 2017; Williamson et al., 2012). COSs can also be used 66 
in other research such as observational studies, and in clinical audit (Potter, Holcombe, Ward, 67 
Blazeby, & Group, 2015; Webbe et al., 2017; Williamson et al., 2017) and practice, as 68 
advocated for by the International Consortium of Health Outcome Measurement (ICHOM). 69 
Another approach to standardised description of diseases and specific health conditions is the 70 
use of the World Health Organisation and the International Classification of Functioning, 71 
Disability and Health (ICF) Research Branch core sets. Guidance on the development of core 72 
sets are outlined elsewhere (Selb et al., 2015; https://www.icf-research-branch.org/icf-core-73 
sets-projects2). Unlike COSs however, ICF core sets aim to describe disease in a standardised 74 
way, rather than standardisation of outcomes in health trials. 75 
  76 
It is important to note that COSs are not necessarily intended to be the only outcomes 77 
measured in a given study. Researchers can measure and report additional outcomes also, but 78 
the COS represents the minimum set of outcomes that should be included (Williamson et al., 79 
2017). The most recent review of COS development identified 307 published COS studies 80 
(Gargon et al., 2018). COSs have been developed across 31 health and disease categories, 81 
including mental health, pregnancy and childbirth, substance dependence, and infectious 82 
diseases (Gargon et al., 2018). The majority of COS studies published to date relate to the 83 
areas of rheumatology, cancer, neurology, and the heart and circulation (Gargon et al., 2018). 84 
The breadth of development of COSs across health areas positions them as a useful tool and 85 
approach for health psychology given the focus on psychological, behavioural and 86 
biobehavioural aspects of health and well-being. Similarly, there is scope to develop COSs 87 
for use in trials of health psychology interventions for a range of health conditions and 88 
behavioural outcomes.  89 
 90 
Developing Core Outcome Sets.  91 
Determining the outcomes to include in a COS is considered the first step of the process that 92 
involves determining what to measure. Once a COS has been developed, how to measure the 93 
COS must then be determined; this is discussed below. The development and use of COSs is 94 
promoted and supported by the Core Outcome Measures in Effectiveness Trials (COMET) 95 
Initiative. The COMET Initiative is an international initiative established in 2010 with the 96 
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aims of raising awareness of existing problems with outcome measurement and reporting; 97 
encouraging evidence-based COS development and uptake; and promoting involvement of 98 
patients (or their representatives), healthcare professionals, and researchers in the 99 
development and uptake of COSs. The COMET Initiative provides resources to support 100 
researchers to develop and use COSs, which are available via their website 101 
(http://www.comet-initiative.org/). Resources include a publicly searchable database of 102 
completed and on-going studies related to COSs, including protocols, systematic reviews and 103 
completed COSs. This facilitates identification of existing COSs for use in research and also 104 
potential for overlap and collaboration with other research groups conducting similar COS 105 
work. Additional resources include a comprehensive COMET Handbook (Williamson et al., 106 
2017) providing guidance on COS development; standards for developing COSs (Kirkham, 107 
Davis, et al., 2017); guidelines for reporting COS protocols (Kirkham et al., 2019); and 108 
reporting of COSs (Kirkham et al., 2016). Each of these guidelines were developed using 109 
rigorous consensus methods, are openly accessible and provide support and guidance 110 
throughout the COS process. The COMET Initiative website also provides useful patient 111 
resources including plain language summaries and videos about COSs (http://www.comet-112 
initiative.org/). 113 
 114 
How to develop a Core Outcome Set. As in-depth guidance on the stages of COS 115 
development following COMET Initiative guidelines is published elsewhere (Kirkham, 116 
Davis, et al., 2017; Kirkham et al., 2016; Kirkham et al., 2019; Williamson et al., 2017) these 117 
stages are only presented in brief here. The first stage is to define the scope of the COS in 118 
terms of the health condition, the target population and the interventions for which the COS 119 
will be applicable (Williamson et al., 2017). The second stage is to assess the need for a COS 120 
by investigating whether a relevant COS already exists. The third and fourth stages are to 121 
develop and register the COS development protocol (Kirkham, Davis, et al., 2017; Kirkham 122 
et al., 2019). The fifth stage involves determining the level and scope of stakeholder 123 
involvement; a checklist of considerations for inclusion of public research partners is 124 
available on the COMET website (http://www.comet-initiative.org/). Stage six, determining 125 
what to measure, involves a number of steps (Williamson et al., 2017); see Figure 1. These 126 
include: a) systematic review(s) to identify all potentially relevant outcomes; b) consideration 127 
of outcome similarities and overlap, c) grouping outcomes into outcome domains, e.g. using 128 
the 38-item COMET taxonomy (Dodd, Williamson, Blazeby, & Clarke, 2017); d) reaching 129 
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consensus on outcomes for inclusion using an online eDelphi (as recommended by COMET), 130 
and a subsequent face-to-face consensus meeting. The end product of these stages is a COS 131 
containing a minimum set of outcomes agreed upon by stakeholders as essential to be 132 
measured and reported in all trials of a specific health outcome. 133 
 134 
How to measure core outcomes. Once agreement has been reached on the what, the next 135 
step is to decide how to measure the outcomes included in the COS. This involves selecting 136 
or developing appropriate outcome measurement instruments (OMIs) or other measurement 137 
approaches. Online resources and tools, such as the National Institute of Health funded 138 
Patient-Reported Outcomes Measurement Information System (PROMIS) can be a useful 139 
resource to select high quality OMIs for commonly relevant outcomes. In the specific context 140 
of core outcome set measurement, the COnsensus-based Standards for the selection of health 141 
Measurement INstruments (COSMIN) Initiative is an international initiative founded in 2005 142 
to promote and support evidence-based selection of the most suitable outcome measurement 143 
instruments. The COSMIN initiative primarily focuses on patient-reported outcome measures 144 
(PROMs) of health status along domains including symptom experiences, functional status, 145 
quality of life, and well-being (Butt, 2016; Fleischmann & Vaughan, 2018). The COSMIN 146 
methodology can also be used for the selection of other OMIs.  147 
COSMIN provides resources and support for identification and selection of outcome 148 
measurement instruments for outcomes within a COS, which are available on the COSMIN 149 
website (www.cosmin.nl). The COSMIN taxonomy of measurement properties for patient-150 
reported health outcomes (Mokkink et al., 2010) for instance, outlines three quality domains, 151 
containing different measurement properties. These domains are reliability, validity, and 152 
responsiveness; interpretability is also included as a quality aspect of OMIs (Mokkink et al., 153 
2010). Prinsen et al. (2016) provide a 4-step guideline on how to select OMIs for COSs. The 154 
first step involves conceptual considerations of the construct and target population. The 155 
second step involves identifying all existing OMIs (see Terwee, Jansma, Riphagen, & de Vet, 156 
2009, and http://database.cosmin.nl for useful resources). The third step involves assessing 157 
the quality of identified OMIs, which can be guided by the COSMIN taxonomy (Mokkink et 158 
al., 2010), the COSMIN 10-step guideline for performing systematic reviews of OMIs 159 
(Prinsen et al., 2018), and the COSMIN Risk of Bias checklist (Mokkink et al., 2018; Terwee 160 
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et al., 2012). The final step involves making recommendations on the selection of OMIs for a 161 
COS (Prinsen et al., 2016).  162 
 163 
Benefits of COSs in Health Psychology 164 
Adopting the use of COSs in health psychology can have a number of beneficial implications 165 
for the field, including evidence syntheses, establishing evidence bases, integrating 166 
stakeholder views, translating research into policy and practice, and conducting research in 167 
an open and transparent manner.  168 
 169 
Evidence syntheses and building empirical bases. Comprehensive evidence syntheses play 170 
an important role in evaluating the global body of evidence on the effectiveness of health 171 
psychology interventions. As noted by Molloy et al. (2018), progressing the science and 172 
practice of health psychology relies on systematic syntheses of evidence from interventions 173 
and trials. These systematic reviews and meta-analyses also provide reliable and clinically 174 
informed aids to decision making in practice (Coyne, Thombs, & Hagedoorn, 2010). 175 
Engagement with and use of COSs facilities improvement of evidence synthesis through 176 
standardisation of outcomes and OMIs used within and across trials.  For instance, use of a 177 
recently developed infant feeding core outcome set for childhood obesity prevention 178 
interventions (Matvienko-Sikar, Byrne, et al., 2018; Matvienko-Sikar, Byrne, et al., 2017) 179 
will standardise outcomes measured across trials in an area with considerable heterogeneity 180 
in outcome assessment (Matvienko-Sikar, Griffin, et al., 2018). As childhood obesity is a 181 
significant global health challenge, this has the potential to improve understanding of 182 
psychologically informed interventions in this area. Using COSs to develop a more 183 
comprehensive evidence base can also inform future intervention development, refinement 184 
and/or adaptation. Use of COSs can also facilitate implementation of treatment interventions 185 
in practice by ensuring that research includes outcomes of importance to patients and 186 
healthcare professionals who make decisions about treatments. This can significantly 187 
improve patient and public health (Heneghan et al., 2017).  188 
 189 
Integration of stakeholder views.  Stakeholder engagement is considered best practice in 190 
health research (Byrne, 2019), and development of COSs involves incorporation of 191 
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perspectives and opinions of key stakeholders at various stages (Williamson et al., 2017). A 192 
recent survey of COS developers indicated that patients, service users, and carers have been 193 
included in 87% of COS development to date, with increased engagement evident over time 194 
(Biggane, Brading, Ravaud, Young, & Williamson, 2018; Gorst et al., 2016). There is also 195 
evidence of increased international stakeholder engagement, for instance in South American 196 
and African countries (Gargon et al., 2018). Stakeholder involvement ensures inclusion of 197 
outcomes of clinical importance and that are relevant to, and reflect priorities of stakeholders 198 
(Biggane et al., 2018; Chalmers et al., 2014;  Byrne, 2019). For instance, rheumatoid arthritis 199 
patient stakeholders identified fatigue as a core outcome to examine in trials, while prior to 200 
this, fatigue was not routinely measured (Kirwan & Hewlett, 2007). Similarly, in 201 
development of a COS for trials of interventions to optimise prescribing in older adult care 202 
homes, 41 outcomes were identified from interviews and focus groups with stakeholders that 203 
were not identified in a systematic review of outcomes (Millar et al., 2017).  204 
 205 
Inclusion of stakeholders in COS development also increases the likelihood of COS uptake 206 
and use (Staniszewska & Denegri, 2013). For instance, a recent examination with patients, 207 
healthcare providers, industry and regulatory agency representatives found that engagement 208 
of end-users in COS development is a key factor in influencing uptake of rheumatology 209 
COSs (Tunis et al., 2017). Similarly, a qualitative study of nephrologists perspectives of 210 
COSs in haemodialysis found that buy-in from gatekeeper stakeholders, such as dialysis 211 
providers, is important for COS uptake and implementation (Tong et al. 2017). The use of 212 
stakeholder engagement and patient and public involvement (PPI) in the development and 213 
use of COSs in health psychology can therefore have a significant and sustained impact on 214 
health psychology research, clinical practice (Biggane et al., 2018) and healthcare provision 215 
(Kirkham, Clarke, et al., 2017). 216 
 217 
Translation of research into policy and practice. Ensuring that health psychology research 218 
findings can be translated and used in policy and practice is essential for effecting meaningful 219 
change. Translation is the process of adapting research findings to clinical and public health 220 
practice (Michie et al., 2013) that facilitates reduction of gaps between research and evidence 221 
based practice (Holmes, Scarrow, & Schellenberg, 2012). It has been noted that it can take up 222 
to 17 years for research findings to influence healthcare (Morris, Wooding, & Grant, 2011). 223 
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One reason why clinical trial findings are often not translated into policy and practice is 224 
inappropriate choice of outcomes (Heneghan et al., 2017). As noted, inclusion of 225 
stakeholders, including policy makers, ensures that relevant and appropriate outcomes are 226 
measured and increases likelihood of uptake and use of COS in relevant contexts, such as in 227 
policy and practice. Similarly, organisations and funding bodies can advocate for the use of 228 
COSs (Hughes et al., 2019). For instance, the National Institute of Health Research in the UK 229 
and Health Research Board in Ireland specify that funding applications consider and include 230 
COSs where available and appropriate (HRB, 2018; NIHR, 2019). To date, there is limited 231 
evidence to support increased translation of research findings resulting from inclusion of 232 
stakeholders in COS development and uptake. However, this is reflective of existing 233 
challenges and gaps in knowledge of how best to translate of much health research, including 234 
health psychology, into policy and practice (Brownson & Jones, 2009; Kazak & Steele, 2011; 235 
McAteer, Di Ruggiero, Fraser, & Frank, 2018; Michie et al., 2013). 236 
 237 
Open Research. Recent evidence of replication and reproducibility issues in psychology 238 
(Open Science, 2015), including in health psychology (Cybulski, Mayo-Wilson, & Grant, 239 
2016), highlight issues related to openness and transparency in research conduct and 240 
reporting. Open and transparent research approaches are paramount to improve scientific 241 
rigour (Cybulski et al., 2016; Hagger, 2019; Open Science, 2015), and a more transparent and 242 
open approach to health research has been called for in a recent editorial in Health 243 
Psychology Review (Hagger, 2019). Open research is based on principles of sharing, fairness, 244 
inclusion and equity, and an important rationale of open science is that knowledge is a 245 
product of social collaboration (Bezjak et al., 2018). COS development adopts this approach 246 
from the outset through inclusion and integration of stakeholder views and input in 247 
determining what should be measured in trials in specific health areas. In this sense COS 248 
development is aligned with the aim of open research to change the value, conduct and 249 
dissemination of research, and who is involved in these processes (Bezjak et al., 2018). As 250 
noted previously, standardisation of outcome examination and reporting using COSs can also 251 
improve conduct and reporting of trials, with potential to minimise issues such as outcome 252 





COS Challenges 256 
Despite the importance and perceived usefulness of incorporating COSs in health 257 
psychology, a number of challenges exist in relation to their development and use. COS 258 
development requirements can be context specific and so not all COS development projects 259 
will encounter the same challenges. A summary of some main challenges in COS 260 
development is presented here. Firstly, given the multiple stages involved in development of 261 
COSs and associated OMIs, the process can be time consuming and labour intensive. Using 262 
technologies such as videoconferencing for stakeholder meetings, as has been done in a 263 
number of COS and OMI development studies (Beuscart et al., 2018; Williamson et al., 264 
2017), can help minimise some cost and resource issues. Research is also on-going to identify 265 
more resource friendly approaches to COS development (Gorst et al. 2019), such as through 266 
development of conceptual frameworks and item banks (Korst et al., 2018). However, 267 
availability and appropriate consideration of financial support and funding needed for COS 268 
development, including for researchers working on COS development, remains important for 269 
successful and timely completion and dissemination of COSs. Better support for development 270 
of COSs from research funders, through project or trial methodology funding is needed. 271 
Given the systematic approaches to development of COSs and OMIs, funders can be 272 
confident in robust scientific methods underlying such research The Health Research Board 273 
in Ireland for instance, currently has funding built in to a larger funding stream around trials 274 
of interventions, to support development of COS. While the impact of this funding support 275 
has yet to be seen, it is a clear step in the right direction of supporting researchers to better 276 
determine the core outcomes to include in trials of health interventions.  277 
 278 
Other challenges related to enabling and facilitating meaningful stakeholder engagement and 279 
contribution across stages of COS development. For instance, recruiting sufficient 280 
representative stakeholders from relevant groups, maintaining communication during 281 
development stages, and minimising attrition between rounds of COS development are 282 
challenging (Biggane et al., 2018). Engaging and involving stakeholders from low and 283 
middle-income countries is also important to improve the international applicability of COSs 284 
and the trials in which they are used (Davis et al. 2018). To date, only 16% of COSs have 285 
included stakeholders from low and middle-income countries however, and so efforts should 286 
be improved to include these stakeholders (Davis et al., 2018). Challenges of stakeholder 287 
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engagement in the selection of OMIs in particular relate to evaluating the quality of OMIs, 288 
which may be beyond the remit of stakeholder input. The COMET handbook (Williamson et 289 
al., 2017) and COSMIN guidance (Prinsen et al., 2016) provide potential solutions to some of 290 
these issues and so they will not be outlined further here. Finally, where COSs include a large 291 
number of outcomes requiring full and appropriate reporting this could prove challenging in 292 
some instances due to journal word counts. Approaches such as use of supplementary files 293 
accompanying publications can ensure that all outcomes are reported and accessible however. 294 
In addition, there are initiatives to support publication of COSs within journals. One such 295 
example is the CoRe Outcomes in WOmen’s and Newborn health (CROWN) Initiative, 296 




COSs represent a useful approach for conducting, reporting, and improving health 301 
psychology research. Development and use of COSs in health psychology can lead to better 302 
conduct and reporting of trials, and more cohesive and robust evidence syntheses that 303 
enhance knowledge and implementation of health interventions. This can lead to significant 304 
beneficial impacts on future health psychology research and the application of research 305 
finding in policy and practice. In addition, COSs can help to promote open and transparent 306 
health psychology research practices. Overall, COS can help to move health psychology 307 
research forward through these processes, and through stakeholder engagement, leading to 308 
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